The ANSWER randomised-controlled trial (RCT) has shown that long-term albumin (LTA) treatment in patients with cirrhosis and uncomplicated ascites improves 18-month overall survival rates, facilitates the management of ascites, and lowers the incidence of severe complications, thus reducing hospitalizations and improving patients’ quality of life.1 Here, ALB is linked to Cirrhosis.